Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02905227 · ClinicalTrials.gov registry record · Phase 1
A Study of the Pulmonary Safety and Pharmacokinetics of Zolmitriptan Inhalation Powder
A Phase 1 study of Migraine, sponsored by Acorda Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
- 3
- Study locations
NCT02905227 is a Phase 1 study of Migraine that has completed, run by Acorda Therapeutics. The registered enrollment target is 60 participants, below the 358-participant average among 102 other Migraine trials with a reported enrollment target (83% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT02905227, a Phase 1 study of Migraine, has completed, sponsored by Acorda Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
- 3
- Study locations
Study Summary
This study is an open-label, parallel group study to evaluate acute pulmonary safety and Pharmacokinetics (PK) of two doses, separated by 2 hours, of CVT-427 zolmitriptan inhalation powder in three groups of adults: those with asthma, those who smoke and healthy volunteers.
Conditions Studied
Interventions
- DRUG CVT-427 (zolmitriptan inhalation powder)
Study Locations (3)
Massachusetts
- Site #103 - North Dartmouth
Nebraska
- Site #102 - Lincoln
Texas
- Site #101 - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2016-09 |
| Est. Completion | 2016-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02905227
The ClinicalTrials.gov registry entry for NCT02905227 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 358-participant average among 102 other Migraine trials with a reported enrollment target (83% lower). The listed sponsor is Acorda Therapeutics, which has 36 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Migraine appearing as the primary indexed condition, and to 1 intervention - of which CVT-427 (zolmitriptan inhalation powder) is the first listed.
NCT02905227 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Massachusetts, Nebraska, Texas.
Frequently Asked Questions
What is clinical trial NCT02905227 about?
NCT02905227 is a clinical study titled "A Study of the Pulmonary Safety and Pharmacokinetics of Zolmitriptan Inhalation Powder". This study is an open-label, parallel group study to evaluate acute pulmonary safety and Pharmacokinetics (PK) of two doses, separated by 2 hours, of CVT-427 zolmitriptan inhalation powder in three groups of adults: those with asthma, those who smoke and healthy volunteers.
What is the current status of trial NCT02905227?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2016-09. Estimated completion is 2016-12.
What conditions does trial NCT02905227 study?
This clinical trial studies the following conditions: Migraine.
What interventions are being tested in trial NCT02905227?
The interventions under investigation include: CVT-427 (zolmitriptan inhalation powder) (DRUG).
Who is sponsoring clinical trial NCT02905227?
This trial is sponsored by Acorda Therapeutics, which has 36 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02905227 being conducted?
This trial has 3 study locations across Massachusetts, Nebraska, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effect of Single Oral Doses of Lasmiditan When Coadministered With Single Oral Doses of Sumatriptan in Healthy Participants
COMPLETED · Phase 1
-
Safety and Pharmacokinetics (PK) Study of Single Ascending Doses of CVT-427 (Zolmitriptan Inhalation Powder) In Healthy Adults
COMPLETED · Phase 1
-
Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine
COMPLETED · Phase 1
-
A Phase I Study to Study the PK and Safety of Single Doses of STS101, DHE Injection and Nasal Spray in Healthy Subjects
COMPLETED · Phase 1
-
A Study Investigating the Movement of Lu AG09222 Into, Through, and Out of the Body of Healthy Caucasian, Chinese, and Japanese Participants
COMPLETED · Phase 1
-
Migraine Manager (R01)
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.